Onco-Innovations Advances PNKP Inhibitor Technology Scaling

Onco-Innovations Limited has announced the launch of process development and scale-up activities for its API, A83B4C63, a key component of its ONC010 drug candidate. This development represents a critical phase in the company's strategy towards IND-enabling studies as it paves the way for First-in-Human clinical trials. The focus will be on refining synthetic processes and scaling production of essential intermediates.

The initiative will be undertaken in collaboration with Dalton Pharma Services, aligning production processes with future GMP requirements. The goal is to maintain high-purity material production for preclinical development. This step aims to ensure the robustness and scalability necessary for the company's future clinical supply needs.

CEO Thomas O'Shaughnessy emphasized the importance of this advancement in translating scientific innovation into clinical applications, underscoring the company's commitment to a disciplined execution strategy.